David Harris is a Cardiology physician affiliated with University of Cincinnati. OpenAlex indexes 115 publications with 3,489 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
231 Albert Sabin Way
Cincinnati, OH 452672827
Telephone
513-588-4548Registry record last updated 23 Jul 2013.
Clinical trials
- Left Atrial Volume Index and Left Atrial Appendage Flow Velocities
Sponsor: University of Cincinnati
- Pericardial Fat and Inflammation in HIV Patients and Controls
Sponsor: University of Cincinnati
- PinPointe FootLaser for the Treatment of Onychomycosis
Sponsor: PathoLase, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Edwards Lifesciences CorporationProgram year20251 payment
- Stryker CorporationProgram year20251 payment
- AltaThera Pharmaceuticals LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86.8%Statin19.9%Atorvastatin Calcium77%Rosuvastatin Calcium24%Part D≥66 patientsBeta blocker18.6%Metoprolol Succinate43%Carvedilol30%Metoprolol Tartrate27%Part D≥34 patients+ 10 more classes in this area
Blood & clotting
12.1%Factor Xa inhibitor8.5%Eliquis77%Xarelto24%Part D<11 patientsP2Y12 inhibitor2.1%Clopidogrel100%Part D≥11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.1%SGLT2 inhibitor1.1%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immunometric and functional measurement of endogenous vasoinhibin in human sera
Frontiers in Endocrinology
2024 - South Asian-Specific MYBPC3Δ25bp Deletion Carriers Display Hypercontraction and Impaired Diastolic Function Under Exercise Stress
Frontiers in Cardiovascular Medicine
2021 - Pheochromocytoma, “the Great Masquerader,” Presenting as Severe Acute Decompensated Heart Failure in a Young Patient
Case Reports in Cardiology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Alberto Espay, MD
University of Cincinnati
Henry Nasrallah, MD
University of Cincinnati
Elyse Lower, MD
University of Cincinnati
Ahmad Sedaghat, MD, PhD
University of Cincinnati
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”